BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $128940.KS readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07205900-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:~HM15275 readout (P2) · Hanmi Pharmaceutical Company Limited $1289
 40.KS
DESCRIPTION:Study to Evaluate HM15275 in Obese or Overweight Subjects Witho
 ut Diabetes Mellitus\n\nPrimary completion date: 2027-01 (estimated) — m
 onth only\, shown on the 1st\nPhase 2 · Cardio-Met · Obese\, Obesity\nEn
 rollment: 267 · Sites: 14\n\nPrimary completion = last participant's prim
 ary-endpoint data collected\; topline results usually follow weeks to mont
 hs later. Sponsor-reported\, often an estimate. Not investment advice.\n\n
 https://datacutoff.com/radar.html?nct=NCT07205900\nhttps://clinicaltrials.
 gov/study/NCT07205900
URL:https://datacutoff.com/radar.html?nct=NCT07205900
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07899073-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:~HIP2602 + HPP2602-2 readout (P3) · Hanmi Pharmaceutical Company L
 imited $128940.KS
DESCRIPTION:A Study to Evaluate Efficacy and Safety of HIP2602 in Erectile 
 Dysfunction Patients\n\nPrimary completion date: 2027-09 (estimated) — m
 onth only\, shown on the 1st\nPhase 3 · Neuro · Erectile Dysfunction\nEn
 rollment: 225 · Sites: 1\n\nPrimary completion = last participant's prima
 ry-endpoint data collected\; topline results usually follow weeks to month
 s later. Sponsor-reported\, often an estimate. Not investment advice.\n\nh
 ttps://datacutoff.com/radar.html?nct=NCT07899073\nhttps://clinicaltrials.g
 ov/study/NCT07899073
URL:https://datacutoff.com/radar.html?nct=NCT07899073
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527650-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:~HM15275 readout (P2) · Hanmi Pharmaceutical Company Limited $1289
 40.KS
DESCRIPTION:Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mell
 itus\n\nPrimary completion date: 2027-10 (estimated) — month only\, show
 n on the 1st\nPhase 2 · Cardio-Met · Type 2 Diabetes Mellitus\, T2DM\nEn
 rollment: 180 · Sites: 20\n\nPrimary completion = last participant's prim
 ary-endpoint data collected\; topline results usually follow weeks to mont
 hs later. Sponsor-reported\, often an estimate. Not investment advice.\n\n
 https://datacutoff.com/radar.html?nct=NCT07527650\nhttps://clinicaltrials.
 gov/study/NCT07527650
URL:https://datacutoff.com/radar.html?nct=NCT07527650
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07660796-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:HCP1803-3 readout (P3) · Hanmi Pharmaceutical Company Limited $128
 940.KS
DESCRIPTION:A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patient
 s With Essential Hypertension\n\nPrimary completion date: 2027-10-30 (esti
 mated)\nPhase 3 · Cardio-Met · Hypertension\nEnrollment: 256 · Sites: 1
 \n\nPrimary completion = last participant's primary-endpoint data collecte
 d\; topline results usually follow weeks to months later. Sponsor-reported
 \, often an estimate. Not investment advice.\n\nhttps://datacutoff.com/rad
 ar.html?nct=NCT07660796\nhttps://clinicaltrials.gov/study/NCT07660796
URL:https://datacutoff.com/radar.html?nct=NCT07660796
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07379333-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:~HM11260C readout (P3) · Hanmi Pharmaceutical Company Limited $128
 940.KS
DESCRIPTION:A Study to Evaluate Efficacy and Safety of HM11260C in Patients
  With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and 
 Dapagliflozin\n\nPrimary completion date: 2027-11 (estimated) — month on
 ly\, shown on the 1st\nPhase 3 · Cardio-Met · Type 2 Diabetes\nEnrollmen
 t: 118 · Sites: 1\n\nPrimary completion = last participant's primary-endp
 oint data collected\; topline results usually follow weeks to months later
 . Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps://
 datacutoff.com/radar.html?nct=NCT07379333\nhttps://clinicaltrials.gov/stud
 y/NCT07379333
URL:https://datacutoff.com/radar.html?nct=NCT07379333
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
